After earnings plunge, BioNTech pins hopes on cancer drug launches
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BioNTech (BNTX) PT Lowered to $95 at TD Cowen
March 21, 2024 10:29 AM EDTTD Cowen analyst Yaron Werber lowered the price target on BioNTech (NASDAQ: BNTX) to $95.00 (from $101.00) while maintaining a Market Perform rating.
The analyst comments "1.5B in Q4 Comirnaty sales missed consensus 1.8B due to write-downs from PFE & waning demand for COVID-19 boosters. FY24 revs... More
Canaccord Genuity Reviews BioNTech (BNTX) Post Earnings
March 21, 2024 7:29 AM EDTCanaccord Genuity analyst William Maughan reiterated a Buy rating and $171.00 price target on BioNTech (NASDAQ: BNTX).
The analyst comments "Shares of BNTX are down 8% (-1% NBI) today after BioNTech presented FY23/4Q23 results. FY23 revenue of 3.8B was roughly in line with previous guidance of 4B, while FY24 guidance was updated to 2.5-3.1B (prev. ~3B). Both of those updates are incrementally below previous expectations, which... More
BioNTech (BNTX) PT Lowered to $123 at BMO Capital
March 21, 2024 6:31 AM EDTBMO Capital analyst Etzer Darout lowered the price target on BioNTech (NASDAQ: BNTX) to $123.00 (from $127.00) while maintaining a Outperform rating.
The analyst comments "BNTX reported FY23 revenues of 3.8B vs. our 4.3B and FY24 revenue guidance of 2.53.1B vs. our 3.1B. While BNTX's financial... More
BioNTech (BNTX) PT Lowered to $91 at Goldman Sachs
March 21, 2024 4:48 AM EDTGoldman Sachs analyst Chris Shibutani lowered the price target on BioNTech (NASDAQ: BNTX) to $91.00 (from $100.00) while maintaining a Neutral rating.
The analyst comments "BNTX reported 4Q23 earnings with Comirnaty (COVID-19 vaccine) sales coming in below expectations (1.48bn vs GS/Visible Alpha Consensus Data... More
JPMorgan Continues to See 2024 AS an 'execution year' for BioNTech (BNTX)
March 20, 2024 2:37 PM EDTJPMorgan analyst Jessica Fye reiterated a Neutral rating and {REMOVEPT} price target on BioNTech (NASDAQ: BNTX)
The analyst comments "We continue to view 2024 as an execution year for BNTX with an aim to set the company up to achieve its longer-term goals (e.g., targeting... More
